Cells in the human body communicate their health status to the immune system by degrading cellular proteins and presenting fragments of each on the cell surface in association class I MHC proteins. Appropriately educated, cytotoxic T-lymphocytes (CTL) (CD8+ T-cells) bind to the class I MHC molecules on the cell surface, sample the protein fragments (peptides) being presented and kill those cells that express new peptides as a result of viral, bacterial and parasitic infection, tissue transplantation and cellular transformation (cancer). Since dysregulation of cell signaling pathways is one of the hallmarks of cancer, we hypothesized that class I MHC phosphopeptides that result from these pathways should be excellent candidates for use in the immunotherapy of cancer. Class I MHC phosphopeptides identified in preliminary work on leukemia, melanoma, and colorectal cancers elicit pre-existing, central-memory, T-cell-recall responses in multiple, healthy blood donors. Central memory recall responses to phosphopeptide antigens is absent in some leukemia patients and correlates with clinical outcome. The response is restored following allogenic stem cell transplantation. These results suggest strongly that class I MHC phosphopeptides are tumor targets of immune surveillance in humans and, therefore, are likely candidates for immunotherapy of cancer. Three of the discovered phosphopeptides will be the subject of a phase I clinical trial on melanoma later this spring. Proposed here is additional research to complete our studies on melanoma, leukemia, and colorectal cancer and to begin an effort to characterize class I MHC phosphopetides presented on esophageal, liver and ovarian cancer. Additional research will be conducted to identify the repertoire of altered class I or class II self-peptides that are induced by prescription drugs or environmental agents and lead to life threatening autoimmune disease. Also proposed is the development novel mass spectrometry technology that will facilitate near complete amino acid sequence coverage of intact therapeutic antibodies and other proteins at the high femtomole level on a chromatographic time scale. This will be accomplished by a combination protein chemical derivatization, changes to existing instrument hardware, enhanced performance of ion-ion chemistry inside the instrument, and modifications to the instrument control software. This approach should accelerate the development of therapeutic antibodies for multiple diseases and also facilitate complete characterization of proteins and protein complexes that contain multiple posttranslational modifications on the same protein molecule.

Public Health Relevance

Proposed here is research;(a) to develop new mass spectrometry instrumentation and methods for the complete sequence analysis of therapeutic antibodies and other intact proteins and (b) to identify class I MHC phosphopeptides that result from dysregulated signal transduction pathways associated with cellular transformation and that stimulate the adaptive immune system to control melanoma, multiple leukemias, plus colorectal, ovarian, liver and esophageal cancer. Characterization of class I and class II MHC peptides that trigger prescription-drug induced and life threatening autoimmune diseases is another objective of the proposed research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Enabling Bioanalytical and Imaging Technologies Study Section (EBIT)
Program Officer
Gondre-Lewis, Timothy A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Virginia
Schools of Arts and Sciences
United States
Zip Code
Pavlos, Rebecca; McKinnon, Elizabeth J; Ostrov, David A et al. (2017) Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Sci Rep 7:8653
Bergmann, Tobias; Lindvall, Mikaela; Moore, Erin et al. (2017) Peptide-binding motifs of two common equine class I MHC molecules in Thoroughbred horses. Immunogenetics 69:351-358
Malaker, Stacy A; Penny, Sarah A; Steadman, Lora G et al. (2017) Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. Cancer Immunol Res 5:376-384
Weisbrod, Chad R; Kaiser, Nathan K; Syka, John E P et al. (2017) Front-End Electron Transfer Dissociation Coupled to a 21 Tesla FT-ICR Mass Spectrometer for Intact Protein Sequence Analysis. J Am Soc Mass Spectrom 28:1787-1795
Mohammed, Fiyaz; Stones, Daniel H; Zarling, Angela L et al. (2017) The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget :
Malaker, Stacy A; Ferracane, Michael J; Depontieu, Florence R et al. (2017) Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. J Proteome Res 16:228-237
Mohammed, Fiyaz; Stones, Daniel H; Zarling, Angela L et al. (2017) The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget 8:54160-54172
Sim, Malcolm J W; Malaker, Stacy A; Khan, Ayesha et al. (2017) Canonical and Cross-reactive Binding of NK Cell Inhibitory Receptors to HLA-C Allotypes Is Dictated by Peptides Bound to HLA-C. Front Immunol 8:193
Sidney, John; Schloss, Jennifer; Moore, Carrie et al. (2016) Characterization of the peptide binding specificity of the HLA class I alleles B*38:01 and B*39:06. Immunogenetics 68:231-6
Zhang, Lichao; English, A Michelle; Bai, Dina L et al. (2016) Analysis of Monoclonal Antibody Sequence and Post-translational Modifications by Time-controlled Proteolysis and Tandem Mass Spectrometry. Mol Cell Proteomics 15:1479-88

Showing the most recent 10 out of 58 publications